ClinicalTrials.gg
RecruitingNCT07144930Updated Aug 28, 2026

Cognitive-Motor Incorporated Training and Its Relations in Cerebrovascular Diseases With Cognitive and Motor Impairments

An interventional study of MCIT program and Motor training program in Moyamoya Disease, Healthy and Stroke, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
20 Years to 100 Years
Sex
All
01

Study summary

The following three-part proposal will explore the impact of applying motor-cognitive incorporated training (MCIT) in individuals with post-stroke cognitive impairment (PSCI) or Moyamoya disease (MMD), and examine the relationship between cognitive and motor impairments and brain activation patterns in these populations.

Part I is a cross-sectional study designed to characterize cognitive and motor performance and their relationship with brain activation patterns in individuals with post-stroke cognitive impairment (PSCI) or Moyamoya disease (MMD), compared to age-matched healthy controls. Thirty participants will be screened for eligibility and recruited for each group (90 participants total). After collecting basic data, all participants will undergo cognitive and motor function tests. Cognitive function tests include tests of global cognition, and executive function. Motor function tests include tests of sensorimotor function, single and dual task standing, muscle strength, and ambulation ability. Functional near-infrared spectroscopy (fNIRS) will be used to evaluate the brain activation during the cognitive tests, and single and dual task standing. Results from all tests will be used to determine the motor, cognitive, and other functional performance, and will be used in the design of the training program in Part II and III.

Part II and III are single-blinded randomized controlled trials that will explore the short and long-term effects of a motor-cognitive incorporated training (MCIT) on motor, and cognitive function in individuals with post-stroke cognitive impairment (PSCI) or Moyamoya disease (MMD). 60 individuals with PSCI (Part II), and 60 individuals with MMD (Part III) will be recruited. After screening for eligibility and collection of demographic data, participants will undergo a pretest assessment. In addition to the motor and cognitive tests used in Part I, stroke location, and time of onset will also be collected for each participant. Brain activation will be assessed during the cognitive tests, single and dual task standing assessments using fNIRS. Participants will be randomly allocated to one of the two groups (MCIT group and active control group) (n=30 in each group) via a sealed envelope selected by a blinded assistant. The training protocol is 30 minutes per session, 3 sessions per week for a total of 4 weeks. The control group will receive motor training only, including upper and lower extremity exercises, bed mobility, strengthening (core and extremities), and balance training, progressing from static to dynamic tasks. The MCIT group will engage in the program combines motor and cognitive training that starts with attention and short-term memory tasks, advancing to working memory and inhibitory control with increasing difficulty. A post-test will be conducted after the 4-week intervention, followed by follow-up assessments at 1, 3, and 12 months for individuals with PSCI or MMD in both the control group and the MCIT group. At the 3-month follow-up, participants who are unable to attend in person will be contacted by telephone. At the 12-month follow-up, all participants will receive a telephone interview focused on return-to-work status.

02

Conditions studied

  • Moyamoya Disease
  • Healthy
  • Stroke

Keywords

  • Stroke
  • Motor-cognitive incorporated training
  • Cognitive function
  • Motor function
  • Post-stroke cognitive impairment
03

In context

Moyamoya Disease

62 studies on the registry are indexed under Moyamoya Disease; 30 are open to participants now.

This study's planned enrollment of 210 is above the median of 73 across 32 interventional studies indexed under Moyamoya Disease.

Browse Moyamoya Disease studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 575 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Part 1:

Inclusion Criteria:

  • For aged-matched healthy controls:

    1. being 20 years of age or older
    2. the ability to stand for more than 30 seconds
    3. a score of higher than 26.
  • For PSCI participants:

    1. Diagnosis of stroke confirmed by brain CT or MRI, with symptom onset more than 7 days prior (subacute or chronic phase)
    2. Being 20 years of age or older
    3. The ability to stand for more than 30 seconds
    4. a MoCA score of less than 26
  • For the MMD group:

    1. a confirmed diagnosis of Moyamoya disease or Moyamoya syndrome through CT scan or angiography
    2. If stroke occurred, being in the subacute phase (one week post-stroke)
    3. being 20 years of age or older
    4. the ability to stand for more than 30 seconds
    5. a MoCA score of less than 26

Exclusion Criteria:

  1. unstable or uncontrolled vital signs, including a resting heart rate >100 or \<40 BPM, a respiratory rate >20 or \<12 breaths per minute, an SpO2 \< 95%, a central arterial pressure (CAP) \<80 mmHg, and individuals requiring ICP monitoring will also be excluded
  2. requiring invasive mechanical ventilation or being deemed unsuitable by the attending physician due to unstable medical conditions
  3. the presence of other neurological disorders or unstable vital signs may interfere with the experiment
  4. currently hospitalized in the intensive care unit (ICU)
  5. Severe visual or hearing impairments, or communication and comprehension difficulties that interfere with study participation

Part 2:

Inclusion Criteria:

  1. Diagnosis of stroke confirmed by brain CT or MRI, with symptom onset more than 7 days prior (subacute or chronic phase)
  2. Being 20 years of age or older
  3. The ability to stand for more than 30 seconds
  4. a MoCA score of less than 26

Exclusion Criteria:

  1. unstable or uncontrolled vital signs, including a resting heart rate >100 or \<40 BPM, a respiratory rate >20 or \<12 breaths per minute, an SpO2 \< 95%, a central arterial pressure (CAP) \<80 mmHg, and individuals requiring ICP monitoring will also be excluded
  2. requiring invasive mechanical ventilation or being deemed unsuitable by the attending physician due to unstable medical conditions
  3. the presence of other neurological disorders or unstable vital signs may interfere with the experiment
  4. currently hospitalized in the intensive care unit (ICU)
  5. Severe visual or hearing impairments, or communication and comprehension difficulties that interfere with study participation

Part 3:

Inclusion Criteria:

  1. Moyamoya disease/syndrome confirmed through CT scan or angiography
  2. being in the subacute phase, defined as one week after stroke onset
  3. being 20 years of age or older
  4. the ability to stand for more than 30 seconds
  5. a Montreal Cognitive Assessment (MoCA) score of less than 26.

Exclusion Criteria:

  1. unstable or uncontrolled vital signs, including a resting heart rate >100 or \<40 BPM, a respiratory rate >20 or \<12 breaths per minute, an SpO2 \< 95%, a central arterial pressure (CAP) \<80 mmHg, and individuals requiring ICP monitoring will also be excluded
  2. requiring invasive mechanical ventilation or being deemed unsuitable by the attending physician due to unstable medical conditions
  3. the presence of other neurological disorders or unstable vital signs that could interfere with the experiment
  4. currently hospitalized in the intensive care unit (ICU)
  5. Severe visual or hearing impairments, or communication and comprehension difficulties that interfere with study participation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
210 participants (estimated)

Study arms

  • No intervention
    No Intervention: Healthy adults

    Year 1: To characterize cognitive and motor performance and its relationship with brain activation patterns in individuals with post-stroke cognitive impairment (PSCI) and Moyamoya Disease (MMD).

  • No intervention
    Individuals with post-stroke cognitive impairment

    Year 1: To characterize cognitive and motor performance and its relationship with brain activation patterns in individuals with post-stroke cognitive impairment (PSCI) and Moyamoya Disease (MMD).

  • No intervention
    Individuals with Moyamoya Disease

    Year 1: To characterize cognitive and motor performance and its relationship with brain activation patterns in individuals with post-stroke cognitive impairment (PSCI) and Moyamoya Disease (MMD).

  • Experimental
    Post-stroke cognitive impairment with MCIT program

    Year 2-3: To evaluate the short- and long-term efficacy of Motor-Cognitive Incorporated Training (MCIT) in improving cognitive and motor outcomes and modulating brain activation patterns in PSCI individuals.

    Other: MCIT program

  • Active comparator
    Post-stroke cognitive impairment with motor training program

    Year 2-3: To evaluate the short- and long-term efficacy of Motor-Cognitive Incorporated Training (MCIT) in improving cognitive and motor outcomes and modulating brain activation patterns in PSCI individuals.

    Other: Motor training program

  • Experimental
    Moyamoya Disease with MCIT program

    Year 2-3: To evaluate the short- and long-term efficacy of MCIT in improving cognitive and motor outcomes and modulating brain activation patterns in MMD individuals.

    Other: MCIT program

  • Active comparator
    Moyamoya Disease with motor training program

    Year 2-3: To evaluate the short- and long-term efficacy of MCIT in improving cognitive and motor outcomes and modulating brain activation patterns in MMD individuals.

    Other: Motor training program

Interventions

  • OtherMCIT program

    The MCIT program combines motor and cognitive training, progressing independently with increasing difficulty. * Motor training, based on traditional physical therapy for stroke patients, includes upper and lower extremity exercises, bed mobility, strengthening (core and extremities), and balance training, progressing from static to dynamic tasks. * Cognitive incorporative component, adapted from previous stroke studies, supports cognitive recovery and overall well-being. Training starts with attention and short-term memory tasks, advancing to working memory and inhibitory control with increasing difficulty. Progression requires an 80% success rate; if not achieved, tasks are simplified by reducing memory span or providing additional guidance.

  • OtherMotor training program

    Based on traditional physical therapy for stroke patients, includes upper and lower extremity exercises, bed mobility, strengthening (core and extremities), and balance training, progressing from static to dynamic tasks. Progression is guided by core action goals (Table 2) and depends on stable vital signs, balance, and minimal assistance. If participants are unable to progress, simpler tasks are provided.

06

What researchers measure

Primary outcomes

  1. Global Cognitive Function

    Global cognitive function will be assessed using the Taiwan 7.1 version of the Montreal Cognitive Assessment (MoCA). The test includes 16 items and 11 categories, evaluating multiple cognitive domains. It has been validated in various clinical populations and countries. Scores range from 0 to 30, higher scores indicate better performance.

    Time frame: Part 1: Baseline (Week 0); Part 2, 3: Baseline (Week 0), immediately post-intervention (Week 5), 4 weeks post-intervention (Week 9), and 12 weeks post-intervention (Week 17)

  2. Task Switching

    The Trail Making Test-A (TMT-A) requires participants to sequentially connect 25 numbered dots, while the Chinese version of TMT-B involves alternating between numbers (1-12) and Chinese zodiac signs (rat to pig). The Chinese TMT-B is a reliable tool for assessing executive function in older adults. Completion time (lower is better) is the primary outcome, with error rates also recorded.

    Time frame: Part 1: Baseline (Week 0); Part 2, 3: Baseline (Week 0), immediately post-intervention (Week 5), 4 weeks post-intervention (Week 9), and 12 weeks post-intervention (Week 17)

  3. Inhibition Control

    The Chinese version of Stroop Color and Word Test (SCWT) consists of two parts: (1) a congruent condition, where participants read color-words printed in matching ink, and (2) an incongruent condition, where they identify the ink color of mismatched color-words (e.g., "black" printed in blue). Participants execute 45 seconds per task, and scores are based on the number of correct responses. Higher scores indicate better performance. The Chinese SCWT is a reliable EF assessment for older adults.

    Time frame: Part 1: Baseline (Week 0); Part 2, 3: Baseline (Week 0), immediately post-intervention (Week 5), 4 weeks post-intervention (Week 9), and 12 weeks post-intervention (Week 17)

  4. Working Memory

    Digit Span Test (DS) consists of 8 items with 2 trials each, starting with 2-digit sequences and increasing to 9 digits. Participants repeat the digits in the order presented, scoring 1 point per correct response. Testing ends when both trials for an item are incorrect. Scores range from 0 to 16, with higher scores indicating better performance.

    Time frame: Part 1: Baseline (Week 0); Part 2, 3: Baseline (Week 0), immediately post-intervention (Week 5), 4 weeks post-intervention (Week 9), and 12 weeks post-intervention (Week 17)

  5. Cognitive Flexibility

    Cognitive flexibility was evaluated using a Naming test. Participants name items within specific categories (fruits, vegetables, modes of transportation). They are given 1 minute to list as many items as possible from a single category, and the total number of correct responses is recorded.

    Time frame: Part 1: Baseline (Week 0); Part 2, 3: Baseline (Week 0), immediately post-intervention (Week 5), 4 weeks post-intervention (Week 9), and 12 weeks post-intervention (Week 17)

  6. Sensorimotor Function

    Sensorimotor function after stroke will be measured by Fugl-Meyer Assessment for upper extremity (FMA-UE) and lower extremity (FMA-LE). The FMA-UE includes subtests evaluating the upper extremity, wrist, hand, and coordination/speed, with scores ranging from 0 to 66. The FMA-LE comprises 17 items that measure reflexes, movement, and coordination of the lower extremity, scored on a 3-point ordinal scale (0-2), with a total score of 34 points. Higher scores indicate better motor recovery. The validity and reliability of both assessments are well established.

    Time frame: Part 1: Baseline (Week 0); Part 2, 3: Baseline (Week 0), immediately post-intervention (Week 5), 4 weeks post-intervention (Week 9), and 12 weeks post-intervention (Week 17)

  7. Muscle Strength

    Bilateral muscle strength of the shoulder flexors, elbow flexors, wrist extensors, ankle flexors/extensors, knee flexors/extensors, hip flexors/extensors, and hip abductors will be measured using a wireless handheld dynamometer (microFET2, Hoggan Industries, Inc., West Jordan, UT, USA). Each muscle group will be tested twice, with participants performing maximal contractions for 6 seconds per trial. A 30-second rest period will be provided between trials to prevent fatigue. The average of the two maximal efforts will be recorded.

    Time frame: Part 1: Baseline (Week 0); Part 2, 3: Baseline (Week 0), immediately post-intervention (Week 5), 4 weeks post-intervention (Week 9), and 12 weeks post-intervention (Week 17)

  8. Ambulation Ability

    Ambulation ability will be evaluated using the Functional Ambulatory Category (FAC), a 6-level scale (0-5). Level 0 indicates the inability to walk, while level 5 represents complete independence. Intermediate levels reflect varying degrees of required assistance or supervision.

    Time frame: Part 1: Baseline (Week 0); Part 2, 3: Baseline (Week 0), immediately post-intervention (Week 5), 4 weeks post-intervention (Week 9), and 12 weeks post-intervention (Week 17)

  9. Dual-Task Cost (DTC)

    Dual-task cost (DTC) will be calculated to perform the difference between single-task and dual-task condition, expressed as a percentage. The DTC will be calculated as: (Dual task measure - Single task measure) / Single task measure x 100%. For the single task, participants will stand still with a feet-together standing posture for 30 seconds, while for the dual task, they will continuously subtract 1 from a random 2-digit number while maintaining standing posture. Each condition will include a 1-minute rest period and will be repeated for three trials to ensure consistency. During the single and dual tasking, kinematic performance will be assessed using the 95% ellipse sway area and RMS sway, recorded by 3 wearable inertial sensors (APDM Mobility Lab® Opal system) placed bilaterally at the ankles and at the 5th lumbar vertebra. Postural sway analysis will include angle (degrees), mean velocity, acceleration, and jerk of the sway trajectory.

    Time frame: Part 1: Baseline (Week 0); Part 2, 3: Baseline (Week 0), immediately post-intervention (Week 5), 4 weeks post-intervention (Week 9), and 12 weeks post-intervention (Week 17)

Secondary outcomes

  1. Oxyhemoglobin [HbO]

    Oxyhemoglobin \[HbO\] will be measured using a multichannel wearable Functional Near-Infrared Spectroscopy (fNIRS) imaging system (NIRSport2, NIRx Medical Technologies LLC, Glen Head, NYC, USA), which emits and receives dual-wavelength near-infrared signals at 760 and 850 nm.

    Time frame: Part 1: Baseline (Week 0); Part 2, 3: Baseline (Week 0), immediately post-intervention (Week 5), 4 weeks post-intervention (Week 9), and 12 weeks post-intervention (Week 17)

  2. Deoxyhemoglobin [HbR]

    Deoxyhemoglobin \[HbR\] will be measured using a multichannel wearable Functional Near-Infrared Spectroscopy (fNIRS) imaging system (NIRSport2, NIRx Medical Technologies LLC, Glen Head, NYC, USA), which emits and receives dual-wavelength near-infrared signals at 760 and 850 nm.

    Time frame: Part 1: Baseline (Week 0); Part 2, 3: Baseline (Week 0), immediately post-intervention (Week 5), 4 weeks post-intervention (Week 9), and 12 weeks post-intervention (Week 17)

  3. Hemoglobin difference levels [Hbdiff]

    Hemoglobin difference levels (Hbdiff) will be measured using a multichannel wearable Functional Near-Infrared Spectroscopy (fNIRS) imaging system (NIRSport2, NIRx Medical Technologies LLC, Glen Head, NYC, USA), which emits and receives dual-wavelength near-infrared signals at 760 and 850 nm.

    Time frame: Part 1: Baseline (Week 0); Part 2, 3: Baseline (Week 0), immediately post-intervention (Week 5), 4 weeks post-intervention (Week 9), and 12 weeks post-intervention (Week 17)

  4. Activity of daily living (ADL)

    The Modified Rankin Scale (mRS) assesses disability levels in ADL, ranging from 0 (no symptoms) to 6 (death). Scores between 1 and 5 reflect increasing levels of disability, from slight (independent) to severe (bedridden), with higher scores indicating lower functional ability.

    Time frame: Part 1: Baseline (Week 0); Part 2, 3: Baseline (Week 0), immediately post-intervention (Week 5), 4 weeks post-intervention (Week 9), and 12 weeks post-intervention (Week 17)

  5. Functional Independence

    The Functional Independence Measure (FIM) will be used to evaluate subjects' ADL abilities. The FIM includes 18 motor and cognitive items, with total scores ranging from 18 to 126. Higher scores indicate greater independence.

    Time frame: Part 1: Baseline (Week 0); Part 2, 3: Baseline (Week 0), immediately post-intervention (Week 5), 4 weeks post-intervention (Week 9), and 12 weeks post-intervention (Week 17)

  6. Instrumental activity of daily living (IADL)

    The Instrumental Activity of Daily Living (IADL) scale evaluates independence across eight domains: telephone use, shopping, food preparation, housekeeping, laundry, transportation, medication management, and financial handling. Scores range from 0 (lowest independence) to 8 (highest independence), with higher scores indicating greater functional ability.

    Time frame: Part 1: Baseline (Week 0); Part 2, 3: Baseline (Week 0), immediately post-intervention (Week 5), 4 weeks post-intervention (Week 9), and 12 weeks post-intervention (Week 17)

  7. Depression

    Depression will be assessed using the Hospital Anxiety and Depression Scale (HADS), specifically the depression subscale. Scores of 8-10 indicate mild depression, 11-14 moderate, and 15-21 severe, with higher scores reflecting greater depressive symptoms.

    Time frame: Part 1: Baseline (Week 0); Part 2, 3: Baseline (Week 0), immediately post-intervention (Week 5), 4 weeks post-intervention (Week 9), and 12 weeks post-intervention (Week 17)

  8. Quality of life (QoL)

    Quality of Life will be measured using the 36-item Short Form Health Survey (SF-36). The validated Taiwanese version will be used, which has strong psychometric properties. Higher scores indicate better health-related quality of life.

    Time frame: Part 1: Baseline (Week 0); Part 2, 3: Baseline (Week 0), immediately post-intervention (Week 5), 4 weeks post-intervention (Week 9), and 12 weeks post-intervention (Week 17)

  9. Return to work

    To track whether participants are able to return to work or re-enter their occupational environment, a telephone interview will be conducted at the 1-year follow-up. If a participant is able to return to work but requires adjustments to their job role or a change in occupation, this information will be documented in detailed notes.

    Time frame: Part 2, 3: 1-year post-intervention

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Aug 2028, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
Aug 28, 2025
StartActual
Jun 23, 2025
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2028
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07144930
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Jun 23, 2025
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Aug 28, 2026

Study contacts

Yan Ci Liu, PhD
Contact
yanciliu@ntu.edu.tw
+886233668135
Yan Ci Liu, PhD
principal investigator · National Taiwan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion